yea, i know i said i would not post for 6 months.. however, as my initial posts had over 1200 hits, i thought i owed it to those of you who might have taken the time to look at geron...today,s p.r, and spike was out of left field, did not see it coming, gravy, has to do with thier partnership with merck { sp ?]and a cancer vaccine... expected news will come, maybe tomorrow, if not, by december. this has to do withgrn163l, which MAY be a cure for cancer.. if you spent some time, at least an hour, you would know what i am talking about !!! again, noone told me to buy microsoft, berkshire hathaway, or amgen when they were at these levels, just trying to put y,all onto somthing that MAY be the equal to all of those.. speaking of amgen, geron just hired the guy who marketed ,the drug that made them go from 1 to 1000 !!! yahoo mssg board is a place to look, many bashers, many pumpers, and a lot of political bull shit, however, there is also a wealth of info for newbies there... i would love to be a fly on the wall in 2 years, when eddie haskell,yyz, texasbc6, top spinner, dan murphey, sponge, and others tell thier children that " yes, i knew about geron when it was a 7 buck stock !!!!!!!!! p.s. peddler, nice buy !!!!
investment idea $$$ update
- Thread starter new redneck
- Start date
This was just posted this afternoon!!
AP
Geron Licenses Immunomic Cancer Rights
Monday November 6, 3:16 pm ET
Geron Licenses Technology Rights From Immunomic for Use in Targeting Cancer-Related Enzyme
NEW YORK (AP) -- Biotech drug developer Geron Corp. said Monday it licensed exclusive patent rights from Immunomic Therapeutics Inc. for the development of cancer vaccines.
Financial terms of the agreement were not disclosed.
The rights cover use of Immunomic's Lamp antigen targeting sequence, a process where immune responses to a given target are amplified.
Under the license, Geron gets worldwide exclusive rights to the Johns Hopkins-owned Lamp patents for cancer vaccines targeting telomerase, an enzyme associated with cancer. Geron will get rights to two more targets in the future.
Geron shares rose 55 cents, or 6.6 percent, to $8.57 in afternoon trading on the Nasdaq.
AP
Geron Licenses Immunomic Cancer Rights
Monday November 6, 3:16 pm ET
Geron Licenses Technology Rights From Immunomic for Use in Targeting Cancer-Related Enzyme
NEW YORK (AP) -- Biotech drug developer Geron Corp. said Monday it licensed exclusive patent rights from Immunomic Therapeutics Inc. for the development of cancer vaccines.
Financial terms of the agreement were not disclosed.
The rights cover use of Immunomic's Lamp antigen targeting sequence, a process where immune responses to a given target are amplified.
Under the license, Geron gets worldwide exclusive rights to the Johns Hopkins-owned Lamp patents for cancer vaccines targeting telomerase, an enzyme associated with cancer. Geron will get rights to two more targets in the future.
Geron shares rose 55 cents, or 6.6 percent, to $8.57 in afternoon trading on the Nasdaq.
big, bad, and ugly
big, bad, and ugly
peddler, if you could post that inteview with the ceo, might open a few eyes here.. ya know, i feel like the father taking his 6 year old daughter for a walk in the park, they come across 2 dogs humping ! the little girl says dad what are they doing, the father says, well the dog in the back has a hurt paw and the one in front is helping him get home... just like ral life she says, you try to help someone out and they fuck you in the ass !!!!!!!!!!!!!!!!!
big, bad, and ugly
peddler, if you could post that inteview with the ceo, might open a few eyes here.. ya know, i feel like the father taking his 6 year old daughter for a walk in the park, they come across 2 dogs humping ! the little girl says dad what are they doing, the father says, well the dog in the back has a hurt paw and the one in front is helping him get home... just like ral life she says, you try to help someone out and they fuck you in the ass !!!!!!!!!!!!!!!!!
GERON LICENSES ANTIGEN TARGETING PATENTS FOR CANCER VACCINE PROGRAM FROM IMMUNOMIC THERAPEUTICS
Joint News Release
MENLO PARK, Calif., and GAITHERSBURG, Md., Nov. 6, 2006 ? Geron Corporation (Nasdaq: GERN) and Immunomic Therapeutics Inc. (ITI) announced today a patent license agreement under which Geron will receive exclusive rights to the LAMP antigen targeting sequence for use in cancer vaccines.
Geron?s therapeutic cancer vaccine, GRNVAC1, triggers an immune response against the universal cancer antigen, telomerase, and uses the LAMP sequence to enhance that immune response. The LAMP technology was invented at Johns Hopkins University and recently licensed to ITI for all applications.
Under the ITI-Geron license, Geron receives worldwide exclusive rights to the Johns Hopkins LAMP patents for cancer vaccines directed to telomerase as well as two additional antigen targets to be selected by Geron at a later date. Financial terms of the agreement were not disclosed.
?GRNVAC1 has demonstrated tolerability and immunogenicity in a Phase I/II clinical trial in metastatic prostate cancer,? said Thomas B. Okarma, Ph.D., M.D., Geron?s president and CEO. ?In addition, results from this trial suggest that the use of the LAMP signal sequence may help to enhance the already potent immune responses seen with telomerase alone. We are pleased to secure rights for the use of the LAMP sequence in GRNVAC1 and future cancer vaccine products.?
The LAMP sequence causes an antigen to which it is attached to be taken up by the lysosomal subcellular compartment of the cell. This has been shown to increase presentation on MHC class II molecules, which in turn, can produce greater CD4+ T-cell responses against the antigen and a more potent and longer lasting overall immune response. A Phase I/II clinical trial of Geron?s GRNVAC1 telomerase cancer vaccine conducted at Duke University has previously shown that addition of the LAMP sequence to the telomerase antigen increased patient CD4+ T-cell responses and improved cytotoxic T-lymphocyte (CTL) mediated killing of cancer cells.
GRNVAC1 is comprised of autologous dendritic cells loaded with telomerase mRNA linked to a LAMP targeting sequence. In March 2005, results of the first completed Phase I/II clinical trial of GRNVAC1 in metastatic prostate cancer patients were published in the Journal of Immunology (JI, 2005, 174:3798-38097).
Geron is a Menlo Park, Calif.-based biopharmaceutical company that is developing and intends to commercialize first-in-class therapeutic products for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The products are based on Geron?s core expertise in telomerase and human embryonic stem cells. For more information, visit www.geron.com.
Immunomic Therapeutics Inc. (ITI) is a privately held biotechnology company headquartered in Gaithersburg, Md., that is commercializing a portfolio of clinical applications based on LAMP vaccine technology. ITI offers access to LAMP-based vectors and novel vaccine design through license and collaborative research agreements. More information about ITI and LAMP technology can be obtained from www.immunomix.com or www.immunomictherapeutics.com.
This news release may contain forward-looking statements made pursuant to the ?safe harbor? provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Geron?s telomerase and cancer vaccine technology constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron?s periodic reports, including the quarterly report on Form 10-Q for the quarter ended September 30, 2006.
CONTACTS:
Media: David Schull, Noonan Russo, 858-546-4810, david.schull@eurorscg.com
Investors: Sharon Weinstein, Noonan Russo, 212-845-4271, sharon.weinstein@eurorscg.com
At Geron: David L. Greenwood, Chief Financial Officer, 650-473-7765, info@geron.com
Joint News Release
MENLO PARK, Calif., and GAITHERSBURG, Md., Nov. 6, 2006 ? Geron Corporation (Nasdaq: GERN) and Immunomic Therapeutics Inc. (ITI) announced today a patent license agreement under which Geron will receive exclusive rights to the LAMP antigen targeting sequence for use in cancer vaccines.
Geron?s therapeutic cancer vaccine, GRNVAC1, triggers an immune response against the universal cancer antigen, telomerase, and uses the LAMP sequence to enhance that immune response. The LAMP technology was invented at Johns Hopkins University and recently licensed to ITI for all applications.
Under the ITI-Geron license, Geron receives worldwide exclusive rights to the Johns Hopkins LAMP patents for cancer vaccines directed to telomerase as well as two additional antigen targets to be selected by Geron at a later date. Financial terms of the agreement were not disclosed.
?GRNVAC1 has demonstrated tolerability and immunogenicity in a Phase I/II clinical trial in metastatic prostate cancer,? said Thomas B. Okarma, Ph.D., M.D., Geron?s president and CEO. ?In addition, results from this trial suggest that the use of the LAMP signal sequence may help to enhance the already potent immune responses seen with telomerase alone. We are pleased to secure rights for the use of the LAMP sequence in GRNVAC1 and future cancer vaccine products.?
The LAMP sequence causes an antigen to which it is attached to be taken up by the lysosomal subcellular compartment of the cell. This has been shown to increase presentation on MHC class II molecules, which in turn, can produce greater CD4+ T-cell responses against the antigen and a more potent and longer lasting overall immune response. A Phase I/II clinical trial of Geron?s GRNVAC1 telomerase cancer vaccine conducted at Duke University has previously shown that addition of the LAMP sequence to the telomerase antigen increased patient CD4+ T-cell responses and improved cytotoxic T-lymphocyte (CTL) mediated killing of cancer cells.
GRNVAC1 is comprised of autologous dendritic cells loaded with telomerase mRNA linked to a LAMP targeting sequence. In March 2005, results of the first completed Phase I/II clinical trial of GRNVAC1 in metastatic prostate cancer patients were published in the Journal of Immunology (JI, 2005, 174:3798-38097).
Geron is a Menlo Park, Calif.-based biopharmaceutical company that is developing and intends to commercialize first-in-class therapeutic products for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The products are based on Geron?s core expertise in telomerase and human embryonic stem cells. For more information, visit www.geron.com.
Immunomic Therapeutics Inc. (ITI) is a privately held biotechnology company headquartered in Gaithersburg, Md., that is commercializing a portfolio of clinical applications based on LAMP vaccine technology. ITI offers access to LAMP-based vectors and novel vaccine design through license and collaborative research agreements. More information about ITI and LAMP technology can be obtained from www.immunomix.com or www.immunomictherapeutics.com.
This news release may contain forward-looking statements made pursuant to the ?safe harbor? provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Geron?s telomerase and cancer vaccine technology constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron?s periodic reports, including the quarterly report on Form 10-Q for the quarter ended September 30, 2006.
CONTACTS:
Media: David Schull, Noonan Russo, 858-546-4810, david.schull@eurorscg.com
Investors: Sharon Weinstein, Noonan Russo, 212-845-4271, sharon.weinstein@eurorscg.com
At Geron: David L. Greenwood, Chief Financial Officer, 650-473-7765, info@geron.com
Redneck you have to remember you can take a horse to water but you can't make it drink.
Not all people understand what they are looking at or looking for. There are probably better stocks out there for people to invest in that might have a higher and quicker return on investment. I have researched and like what I see with Geron. I could be right or I could be wrong. All i know is I already am guaranteed to make money on this one. I put in a stop loss on all my stocks and raise it as the price increases. If a person follows this they can make money or limit losses. Many people don't use stop limit and stop loss.:shrug:
Thanks again for the heads up on this one.:toast:
Not all people understand what they are looking at or looking for. There are probably better stocks out there for people to invest in that might have a higher and quicker return on investment. I have researched and like what I see with Geron. I could be right or I could be wrong. All i know is I already am guaranteed to make money on this one. I put in a stop loss on all my stocks and raise it as the price increases. If a person follows this they can make money or limit losses. Many people don't use stop limit and stop loss.:shrug:
Thanks again for the heads up on this one.:toast:
is this any differant than other scams ?
I have just seen it go on here and even been a victim of this with people telling me stock sure things and then it dont quite turn out that way.
just a differant viewpoint
I have just seen it go on here and even been a victim of this with people telling me stock sure things and then it dont quite turn out that way.
just a differant viewpoint
Come on, Scott. A stock pick is no more of a "scam" than a ML play on a NCAAF favorite. As much as I hate to say so, I agree with Jack that you have look at the info with an open mind.
